B. Metzler seel. Sohn & Co. Holding AG Invests $932,000 in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) in the 3rd quarter, Holdings Channel reports. The fund acquired 36,603 shares of the company’s stock, valued at approximately $932,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Bfsg LLC boosted its position in shares of BridgeBio Pharma by 175.6% during the second quarter. Bfsg LLC now owns 1,240 shares of the company’s stock worth $31,000 after buying an additional 790 shares during the period. Headlands Technologies LLC acquired a new position in shares of BridgeBio Pharma during the second quarter worth about $48,000. Values First Advisors Inc. acquired a new position in BridgeBio Pharma during the third quarter valued at approximately $57,000. CWM LLC boosted its position in BridgeBio Pharma by 132.9% during the third quarter. CWM LLC now owns 3,442 shares of the company’s stock valued at $88,000 after purchasing an additional 1,964 shares during the last quarter. Finally, Amalgamated Bank boosted its position in BridgeBio Pharma by 24.7% during the second quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock valued at $123,000 after purchasing an additional 962 shares during the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Brian C. Stephenson sold 4,156 shares of BridgeBio Pharma stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total value of $93,135.96. Following the transaction, the chief financial officer now owns 93,758 shares in the company, valued at approximately $2,101,116.78. This trade represents a 4.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of BridgeBio Pharma stock in a transaction on Friday, September 13th. The shares were sold at an average price of $25.75, for a total value of $149,350,000.00. Following the completion of the transaction, the insider now owns 25,260,971 shares in the company, valued at approximately $650,470,003.25. The trade was a 18.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,831,545 shares of company stock worth $150,056,923 in the last 90 days. Company insiders own 24.66% of the company’s stock.

BridgeBio Pharma Price Performance

BridgeBio Pharma stock opened at $23.42 on Friday. The stock’s fifty day moving average price is $24.96 and its two-hundred day moving average price is $26.25. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $44.32. The firm has a market cap of $4.43 billion, a PE ratio of -9.72 and a beta of 1.09.

Wall Street Analysts Forecast Growth

BBIO has been the subject of several recent research reports. Oppenheimer initiated coverage on BridgeBio Pharma in a research report on Thursday, October 3rd. They set a “market perform” rating for the company. Evercore ISI reduced their price target on BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. JPMorgan Chase & Co. reduced their price target on BridgeBio Pharma from $46.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Piper Sandler initiated coverage on BridgeBio Pharma in a research report on Wednesday, September 4th. They set an “overweight” rating and a $46.00 price target for the company. Finally, Scotiabank increased their price target on BridgeBio Pharma from $44.00 to $45.00 and gave the company a “sector outperform” rating in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.57.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.